Zobrazeno 1 - 10 of 38 pro vyhledávání: '"Yung-wu Chen"'
1
A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model
Autor: Theresa Chen, J. Ruth Wu-Wong, Phimon Atsawasuwan, Maysaa Oubaidin, Yung-wu Chen, Jerry L. Wessale
Publikováno v: Journal of exploratory research in pharmacology
Background and objectives VS-105, a novel vitamin D receptor agonist with significantly less hypercalcemic side effects than calcitriol, is a useful tool to investigate whether or not a vitamin D receptor agonist at non-hypercalcemic doses could impr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48d9d7cc8d72645a569e7adf24c7f92e
http://europepmc.org/articles/PMC8478347
Zobrazit plný text záznamu
2
Preclinical studies of VS-505: a non-absorbable highly effective phosphate binder
Autor: J. Ruth Wu-Wong, Jonathan T. Wong, Yung-wu Chen, Jerry L. Wessale
Publikováno v: British Journal of Pharmacology. 173:2278-2289
Background and purpose Phosphate imbalance is often present in chronic kidney disease (CKD), and it contributes to a higher cardiovascular mortality rate. A phosphate binder is typically part of a treatment strategy for controlling phosphate imbalanc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c87b9085fa5669929d52a2e9ba48e779
https://doi.org/10.1111/bph.13510
Zobrazit plný text záznamu
3
Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats
Autor: Jerry L. Wessale, Yung-wu Chen, J. Ruth Wu-Wong
Publikováno v: American Journal of Physiology-Renal Physiology. 308:F309-F319
Vitamin D receptor (VDR) agonists (VDRAs) are commonly used to manage hyperparathyroidism secondary to chronic kidney disease (CKD). Patients with CKD experience extremely high risks of cardiovascular morbidity and mortality. Clinical observations sh
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3da55862dba3ea7f23103ab3493403
https://doi.org/10.1152/ajprenal.00129.2014
Zobrazit plný text záznamu
4
Two Novel Vitamin D Receptor Modulators with Similar Structures Exhibit Different Hypercalcemic Effects in 5/6 Nephrectomized Uremic Rats
Autor: J. Ruth Wu-Wong, Yung-wu Chen, Ching-jang Huang, Jerry L. Wessale, Meng-ting Wu, Megumi Kawai, Masaki Nakane
Publikováno v: American Journal of Nephrology. 37:310-319
Background/Aims: Vitamin D receptor modulators (VDRMs) are indicated for secondary hyperparathyroidism in chronic kidney disease (CKD). Clinical observations demonstrate that VDRM therapy provides cardiovascular (CV) benefit in CKD. Current on-market
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a0bfb84fd39384f59df823fde955cd1
https://doi.org/10.1159/000348755
Zobrazit plný text záznamu
5
Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats
Autor: Masafumi Fukagawa, Yung-wu Chen, Kaichiro Sawada, Takatoshi Kakuta, Genta Kanai, J. Ruth Wu-Wong, Jerry L. Wessale
Publikováno v: The Journal of steroid biochemistry and molecular biology. 167
Vitamin D receptor (VDR) agonists (VDRAs) are commonly used to treat secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). Current VDRA therapy often causes hypercalcemia, which is a critical risk for vascular calcificati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292cc720be3a0830770cce2ea23ec723
https://pubmed.ncbi.nlm.nih.gov/27989797
Zobrazit plný text záznamu
8
VS‐105: a novel vitamin D receptor modulator with cardiovascular protective effects
Autor: Megumi Kawai, J. Ruth Wu-Wong, Masaki Nakane, Yung-wu Chen
Publikováno v: British Journal of Pharmacology. 164:551-560
BACKGROUND AND PURPOSE Vitamin D receptor (VDR) modulators (VDRMs) such as calcitriol, paricalcitol and doxercalciferol are commonly used to manage hyperparathyroidism secondary to chronic kidney disease (CKD). CKD patients experience extremely high
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e431321ccbb641e7fb12c6211555cdad
https://doi.org/10.1111/j.1476-5381.2011.01473.x
Zobrazit plný text záznamu
9
Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression
Autor: Stevan W. Djuric, Kennan C. Marsh, Gin C. Hsieh, Michael P. Sheets, Yung-Wu Chen, Thomas A. Fey, Cindy Henry, Karl W. Mollison, Rolf Wagner, Donna M. Gauvin, George W. Carter, James M. Trevillyan, Teresa A. Rosenberg, Sandra E. Burke, Steve J. Ballaron, Joy Bauch, Morey L. Smith
Publikováno v: Journal of Cardiovascular Pharmacology. 49:228-235
Sirolimus (rapamycin) is an immunosuppressant used in preventing allograft rejection and in drug-eluting stents to prevent restenosis after angioplasty. Zotarolimus, an analogue of sirolimus, was designed to have a shorter in vivo half-life. Zotaroli
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d70a94a47632b4c29594455a56393e
https://doi.org/10.1097/fjc.0b013e3180325b0a
Zobrazit plný text záznamu
10
High Glucose Activates Nuclear Factor of Activated T Cells in Native Vascular Smooth Muscle
Autor: Yung-Wu Chen, Lisa M. Nilsson, Jenny Nilsson, David Erlinge, Maria F. Gomez, Jeffery D. Molkentin
Publikováno v: Arteriosclerosis, Thrombosis, and Vascular Biology. 26:794-800
Objective— Hyperglycemia has been suggested to play a role in the development of vascular disease associated with diabetes. Atypical Ca 2+ signaling and gene expression are characteristic of vascular dysfunction; however, little is known regarding
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67483fc94c60700d980e91c213fde0a2
https://doi.org/10.1161/01.atv.0000209513.00765.13
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje